Revisiting CHK1 and WEE1 kinases as therapeutic targets in cancer
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · 2025-11 · 1880 (6) · 189482
DOI: 10.1016/j.bbcan.2025.189482 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2025-11. Verfasst von Nehal Arvind Kumar und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, Sri Ramachandra Faculty of Pharmacy, Sri Ramachandra Institution of Higher Education and Research (Deemed to be Universit…. Hauptthemen laut MEDLINE: Checkpoint Kinase 1, Neoplasms, Protein-Tyrosine Kinases, Cell Cycle Proteins. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 178 Literaturangaben. Gefördert von: Indian Council of Medical Research.
Abstract (Originalsprache)
Uncontrolled cell division is a defining characteristic of cancer, driven by genomic instability. This instability disrupts the DNA damage response network, exacerbates replication stress, and impairs cell cycle checkpoints. Although conventional DNA-damaging therapies like chemotherapy and radiotherapy exploit this vulnerability, they often cause substantial damage to healthy tissues, leading to adverse effects that may inadvertently promote tumour resilience. Targeted DDR inhibition, exemplified by Poly [ADP-ribose] polymerase inhibitors, has achieved major clinical success, functioning through a synthetic lethality approach in tumours with a defective homologous recombination repair pathway. Extending this strategy to the ATR-CHK1-WEE1 axis, a central responder to replication stress and regulator of intra-S and G2/M checkpoints, offers a promising therapeutic window, particularly in cancers with G1/S checkpoint defects. However, realising this potential requires a deeper understanding of tumour-specific DNA damage response defects, identification of robust biomarkers, and improved patient stratification needs. Currently, the clinical development of CHK1 and WEE1 inhibitors demonstrates their potential, especially in combination with standard-of-care therapies, where they capitalise on elevated replication stress to induce selective tumour cell death. This review outlines recent advances, challenges, and future directions in targeting CHK1 and WEE1 kinases, highlighting their potential to advance precision oncology in the future.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology, Sri Ramachandra Faculty of Pharmacy, Sri Ramachandra Institution of Higher Education and Research (Deemed to be University), Chennai, Tamil Nadu, India.
- Department of Pharmacology, Sri Ramachandra Faculty of Pharmacy, Sri Ramachandra Institution of Higher Education and Research (Deemed to be University), Chennai, Tamil Nadu, India. Electronic address: jaikanthc@sriramac…
Förderung
- Indian Council of Medical Research
Zitieren
APA
Kumar, N. A., Manasa, P., & Chandrasekaran, J. (2025). Revisiting CHK1 and WEE1 kinases as therapeutic targets in cancer. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 1880(6), 189482. https://doi.org/10.1016/j.bbcan.2025.189482
Vancouver
Kumar NA, Manasa P, Chandrasekaran J. Revisiting CHK1 and WEE1 kinases as therapeutic targets in cancer. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. 2025;1880(6):189482. doi:10.1016/j.bbcan.2025.189482
BibTeX
@article{Kumar2025,
author = {Kumar, Nehal Arvind and Manasa, P and Chandrasekaran, Jaikanth},
title = {Revisiting CHK1 and WEE1 kinases as therapeutic targets in cancer},
journal = {Biochimica et Biophysica Acta (BBA) - Reviews on Cancer},
year = {2025},
volume = {1880},
number = {6},
pages = {189482},
doi = {10.1016/j.bbcan.2025.189482}
}
EUVIMED